Featured news

Eligo Bioscience signs deal with GSK worth up to $224 million

#CRISPR #SkinMicrobiome #Inflammation

 

The presence or absence of a single bacterial gene can trigger or aggravate a variety of diseasesI

 

 This genetic causality is being demonstrated in a growing number of therapeutic areas 

 

 

Introducing the Eligobiotics®

A first-in-class proprietary technology to change the microbiome genetic signature with unprecedented precision

 “Eligo’s technology could be as important as the discovery of penicillin.”  

– Professor Christian Brechot,
Executive director at Institut Pasteur

We are hiring!

Join Our Team

Our Partners & Investors